ESTRADIOL AND NORETHINDRONE ACETATE Drug Patent Profile
✉ Email this page to a colleague
When do Estradiol And Norethindrone Acetate patents expire, and when can generic versions of Estradiol And Norethindrone Acetate launch?
Estradiol And Norethindrone Acetate is a drug marketed by Barr, Breckenridge Pharm, Naari Pte Ltd, Novast Labs, Teva Pharms Usa, and Xiromed. and is included in six NDAs.
The generic ingredient in ESTRADIOL AND NORETHINDRONE ACETATE is estradiol; norethindrone acetate. There are seventy-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the estradiol; norethindrone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Estradiol And Norethindrone Acetate
A generic version of ESTRADIOL AND NORETHINDRONE ACETATE was approved as estradiol; norethindrone acetate by BRECKENRIDGE PHARM on April 17th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ESTRADIOL AND NORETHINDRONE ACETATE?
- What are the global sales for ESTRADIOL AND NORETHINDRONE ACETATE?
- What is Average Wholesale Price for ESTRADIOL AND NORETHINDRONE ACETATE?
Summary for ESTRADIOL AND NORETHINDRONE ACETATE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 6 |
Clinical Trials: | 36 |
Patent Applications: | 44 |
DailyMed Link: | ESTRADIOL AND NORETHINDRONE ACETATE at DailyMed |
Recent Clinical Trials for ESTRADIOL AND NORETHINDRONE ACETATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bio Genuine (Shanghai) Biotech Co., Ltd. | Phase 3 |
University of Chicago | Phase 4 |
Myovant Sciences GmbH | Phase 4 |
Pharmacology for ESTRADIOL AND NORETHINDRONE ACETATE
Drug Class | Estrogen Progestin |
Mechanism of Action | Estrogen Receptor Agonists |